Posted by Michael Wonder on 09 Oct 2019
A small biotech raises the price on its cancer drug by 20% this year, but will anyone notice?
9 October 2019 - As Puma Biotechnology struggles to meet sales goals and expand usage for its all-important Nerlynx breast cancer treatment, the company has resorted to a tried-and-true tactic for boosting sales — raising prices.
But Puma has taken a step most other drug makers have avoided recently: the wholesale price for Nerlynx not only jumped twice this year, but by 9.9% each time.
In other words, Puma has now increased the price by 20% in just nine months.
